会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明授权
    • Peptides having thymopoietin-like activity
    • 具有胸腺生成素样活性的肽
    • US4397842A
    • 1983-08-09
    • US248759
    • 1981-03-30
    • Gideon GoldsteinGeorge Heavner
    • Gideon GoldsteinGeorge Heavner
    • A61K38/00C07K14/66A61K37/00
    • C07K14/662A61K38/00Y10S930/18
    • There are disclosed peptides having the following formula:A--X--Z--Y--Bwherein A is ##STR1## X is a suitable neutral, aliphatic or aromatic amino acid residue; e.g., one selected from the group consisting of ALA, 2-Me-ALA, GLY, LEU, ILE, LYS, THR, SER, PHE, MET, D-ALA, D-LEU, D-ILE, D-LYS, D-THR, allo-THR, D-SER, D-PHE, D-MET, and SAR; Z is ##STR2## Y is GLY, SER, THR, LEU, ILE, VAL, OR SAR; B IS TYR-R', D-TYR-R', decarboxy-TYR, or ##STR3## m is 3 or 4; n is 1, 2, or 3; R''' is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.6 -C.sub.12 aryl, or C.sub.1 -C.sub.7 alkanoyl; and R and R' are substituents which do not substantially affect the biological activity of the peptides, provided that R-ARG-LYS-ASP-VAL-TYR-R' is excluded. These peptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the peptides, therapeutic compositions, and methods for use of the compositions.
    • 公开了具有下式的肽:A-X-Z-Y-B其中A是合适的中性,脂族或芳族氨基酸残基; 例如选自ALA,2-Me-​​ALA,GLY,LEU,ILE,LYS,THR,SER,PHE,MET,D-ALA,D-LEU,D-ILE,D-LYS,D -THR,allo-THR,D-SER,D-PHE,D-MET和SAR; Z是 Y是GLY,SER,THR,LEU,ILE,VAL或OR SAR; B是TYR-R',D-TYR-R',脱羧-TYR或者 m是3或4; n为1,2或3; R“是氢,C 1 -C 7烷基,C 6 -C 12芳基或C 1 -C 7烷酰基; 并且R和R'是不排除基本上影响肽的生物学活性的取代基,条件是R-ARG-LYS-ASP-VAL-TYR-R'。 这些肽具有诱导T淋巴细胞分化而不是补体受体(CR +)B淋巴细胞分化的能力,因此可用于许多治疗领域。 还提供了肽的衍生物,治疗组合物和组合物的使用方法。
    • 24. 发明授权
    • Peptides having thymopoietin-like activity
    • 具有胸腺生成素样活性的肽
    • US4261886A
    • 1981-04-14
    • US124959
    • 1980-03-13
    • Gideon GoldsteinGeorge Heavner
    • Gideon GoldsteinGeorge Heavner
    • A61K38/00C07K14/66C07C103/52
    • C07K14/662A61K38/00Y10S930/18
    • There are disclosed peptides having the following formula: 12 A-X-Z-Y-Bwherein A is ##STR1## X is a suitable neutral, aliphatic or aromatic amino acid residue; e.g., one selected from the group consisting of ALA, 2-Me-ALA, GLY, LEU, ILE, LYS, THR, SER, PHE, MET, D-ALA, D-LEU, D-ILE, D-LYS, D-THR, allo-THR, D-SER, D-PHE, D-MET, and SAR; Z is ##STR2## Y is GLY, SER, THR, LEU, ILE, VAl, or SAR; B is TYR-R', D-TYR-R', decarboxy-TYR, or ##STR3## m is 3 or 4; n is 1, 2, or 3; R''' is hydrogen, C.sub.1 -C.sub.7 alkyl, C.sub.6 -C.sub.12 aryl, or C.sub.1 -C.sub.7 alkanoyl; and R and R' are substituents which do not substantially affect the biological activity of the peptides, provided that R-ARG-LYS-ASP-VAL-TYR-R' is excluded. These peptides have the capability of inducing the differentiation of T-lymphocytes but not of complement receptor (CR.sup.+) B-lymphocytes and thus are useful in a number of therapeutic areas. Also provided are derivatives of the peptides, therapeutic compositions, and methods for use of the compositions.
    • 公开了具有下式的肽:1 2 A-X-Z-Y-B其中A是合适的中性,脂族或芳族氨基酸残基; 例如选自ALA,2-Me-​​ALA,GLY,LEU,ILE,LYS,THR,SER,PHE,MET,D-ALA,D-LEU,D-ILE,D-LYS,D -THR,allo-THR,D-SER,D-PHE,D-MET和SAR; Z是 Y是GLY,SER,THR,LEU,ILE,VA1或SAR; B是TYR-R',D-TYR-R',脱羧-TYR或者 m是3或4; n为1,2或3; R“是氢,C 1 -C 7烷基,C 6 -C 12芳基或C 1 -C 7烷酰基; 并且R和R'是不排除基本上影响肽的生物学活性的取代基,条件是R-ARG-LYS-ASP-VAL-TYR-R'。 这些肽具有诱导T淋巴细胞分化而不是补体受体(CR +)B淋巴细胞分化的能力,因此可用于许多治疗领域。 还提供了肽的衍生物,治疗组合物和组合物的使用方法。
    • 27. 发明授权
    • Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
    • 生长停滞特异性基因6肽,抗体,组合物,方法和用途
    • US07547767B2
    • 2009-06-16
    • US11602865
    • 2006-11-21
    • Jing YangGeorge HeavnerRobert JordanJill Giles-KomarRay Sweet
    • Jing YangGeorge HeavnerRobert JordanJill Giles-KomarRay Sweet
    • C07K16/46
    • C07K14/745C07K16/18C07K2317/21C07K2317/56C07K2317/76
    • The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.
    • 本发明提供了来自人生长抑制特异性基因6(Gas6)的受体结合区的新型蛋白质和肽,以及对至少一种这样的Gas6肽或其片段特异的包括特定部分或变体的抗体。 上述肽可用于产生人,灵长类动物,啮齿动物,哺乳动物,嵌合,人源化和/或CDR移植的抗Gas6抗体。 本发明还提供了编码这些肽和抗Gas6抗体的核酸,互补核酸,载体,宿主细胞,以及制备和使用它们的方法,包括治疗制剂,给药和装置。 鉴定,分离和合成来自Gas6G结构域的15个新的肽序列,其与其受体相关的Gas6相互作用,以便产生抗Gas6抗体。 肽序列包括三个EST,其包含预期有助于受体结合的区域或可产生抗Gas6抗体。 本发明提供这样的抗体用于调节或治疗细胞,组织,器官,动物或患者中的至少一种Gas6相关疾病。 这些疾病可以包括但不限于血栓栓塞性疾病,缺血性疾病,静脉血栓栓塞,动脉或静脉血栓形成,肺栓塞,再狭窄,糖尿病性血管病和同种异体移植动脉粥样硬化。
    • 28. 发明申请
    • Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
    • 生长停滞特异性基因6肽,抗体,组合物,方法和用途
    • US20070128200A1
    • 2007-06-07
    • US11602865
    • 2006-11-21
    • Jing YangGeorge HeavnerRobert JordanJill Giles-KomarRay Sweet
    • Jing YangGeorge HeavnerRobert JordanJill Giles-KomarRay Sweet
    • A61K39/395C07H21/04C12P21/06C12N5/06C12N1/21
    • C07K14/745C07K16/18C07K2317/21C07K2317/56C07K2317/76
    • The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.
    • 本发明提供了来自人生长抑制特异性基因6(Gas6)的受体结合区的新型蛋白质和肽,以及对至少一种这样的Gas6肽或其片段特异的包括特定部分或变体的抗体。 上述肽可用于产生人,灵长类动物,啮齿动物,哺乳动物,嵌合,人源化和/或CDR移植的抗Gas6抗体。 本发明还提供了编码这些肽和抗Gas6抗体的核酸,互补核酸,载体,宿主细胞,以及制备和使用它们的方法,包括治疗制剂,给药和装置。 鉴定,分离和合成来自Gas6G结构域的15个新的肽序列,其与其受体相关的Gas6相互作用,以便产生抗Gas6抗体。 肽序列包括三个EST,其包含预期有助于受体结合的区域或可产生抗Gas6抗体。 本发明提供这样的抗体用于调节或治疗细胞,组织,器官,动物或患者中的至少一种Gas6相关疾病。 这些疾病可以包括但不限于血栓栓塞性疾病,缺血性疾病,静脉血栓栓塞,动脉或静脉血栓形成,肺栓塞,再狭窄,糖尿病性血管病和同种异体移植动脉粥样硬化。